Reduces LDL-C and ApoB exposure and, for appropriately selected therapies and populations, lowers cardiovascular-event risk.
LONGEVITY & HEALTHY AGING / PRACTITIONER-GUIDED
Cholesterol-lowering medications
Statins, ezetimibe, PCSK9-directed therapies and other medicines lower atherogenic cholesterol through different mechanisms and are selected from total cardiovascular risk—not one isolated number.Create account & prepare for review →Practitioner review required · A prescription is never guaranteed.
Strong outcome evidence supports established therapies for appropriate primary- and secondary-prevention populations.
Prescription required; drug- and indication-specific FDA labeling
WHO MAY BE CONSIDERED
Eligibility starts with your complete health context.
- ✓LDL-C or ApoB burden and overall risk justify medication
- ✓Family history, diabetes, kidney disease, imaging and prior events are considered
- ✓Response, adherence and adverse effects can be monitored
WHAT A PRACTITIONER REVIEWS
The information that shapes the decision.
- →Fasting or nonfasting lipid profile and ApoB when useful
- →Personal and family cardiovascular history
- →Pregnancy context, liver history, muscle symptoms and interacting drugs
IMPORTANT SAFETY INFORMATION
Reasons treatment may not be appropriate.
- !Therapy should be matched to baseline risk and expected absolute benefit.
- !Muscle symptoms, liver concerns and interactions deserve structured review rather than automatic discontinuation.
- !Pregnancy and lactation decisions require product-specific clinical guidance.
ORIGINAL SOURCES